Research location
Komatsushimachō
Tokushima, Japan
Advertisement
Research activity in Komatsushimachō
Tokushima, JapanCureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 7 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Komatsushimachō
7 linked trials · page 1 of 1Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) PatientsNCT02002702 · 2014-01-01 · 1 site observation
COMPLETED
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)NCT01951625 · 2013-11-29 · 1 site observation
COMPLETED
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)NCT01951638 · 2013-11-06 · 1 site observation
COMPLETED
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes MellitusNCT01294436 · 2011-02-01 · 1 site observation
COMPLETED
Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart FailureNCT01115855 · 2010-07-01 · 1 site observation
COMPLETED
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeNCT00968708 · 2009-09-01 · 1 site observation
COMPLETED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 1 site observation
COMPLETED
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.